Protara Therapeutics (TARA)

• Market cap: $121M
• 1 day: -1.88%
• 5 days: -0.32%
• 1 month: 2.28%
• 3 months: -3.68%
• 6 months: -22.85%
• Year to date: -43.73%
• 1 year: 81.5%
• 5 years: -83.82%
• 10 years: -99.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Employees: 33

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

108% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 13

29% more funds holding

Funds holding: 59 [Q1] → 76 (+17) [Q2]

2% more call options, than puts

Call options by funds: $215K | Put options by funds: $210K

1.2% less ownership

Funds ownership: 78.22% [Q1] → 77.02% (-1.2%) [Q2]

27% less capital invested

Capital invested by funds: $124M [Q1] → $90.1M (-$33.7M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]